C3 Jian?s lead product, called C16G2, is a peptide-based antimicrobial drug specifically targeting the bacteria responsible for dental caries, or tooth decay.
?We view this as an investment in exciting research that could potentially stop tooth decay,? said Dennis G. Wilson, president and CEO of Delta Dental.
C3 Jian, based in Los Angeles, recently began phase 2 of its clinical trial to study the product, which is a mouth rinse as well as a gel for dental trays and toothbrush applications.
You can read our related ?Dental Cool? blog posting from 2013 ?A Mouthwash to End Tooth Decay?? about this same research.